| Ytd | -3.89% | |
| 1y | 2.77% |
| Open | 7.49 | Prev Close | 7.47 | Low | 7.25 | High | 7.49 | Mkt Cap | 209.14M |
| Vol | 65.52K | Avg Vol | 248.04K | EPS | -0.22 | P/E | N/A | Forward P/E | -75.83 |
| Beta | 1.08 | Short Ratio | 0.55 | Inst. Own | 24.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 6.82 | 200-d Avg | 6.96 | 1yr Est | 10.00 |
DERM News
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compel
Journey Medical demonstrates strong Emrosi prescription growth, rebounding from Q1 lows with Q2 reve
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy an
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's
Journey Medical Corporation (DERM) Q2 2026 Earnings Call Transcript
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the q
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.01) per share which beat the analyst
SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Jou
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.08 per share versus the Zack
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.08) per share which met the analyst c
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 mill
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
Company to host conference call to discuss financial results and provide a corporate update on May 1
Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 millio
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Bu
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.04) per share which beat the analyst
3,750,000 SHARES OF COMMON STOCKWe have entered into an At Market Issuance Sales Agreement (the "
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.09) per share which missed the analys
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate rele
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM
Lake Street analyst Thomas Flaten maintains Journey Medical (NASDAQ:DERM) with a Buy and raises t
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading afte
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.16) per share which missed the analys
B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and r
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025Expandi
Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "
Journey Medical (NASDAQ:DERM) reported quarterly losses of $(0.18) per share which beat the analyst